KRAS and hepatocellular carcinoma: Therefore, the technology to tracking the NS3 protease activity in vivo would provide a powerful tool to design the personalized protease inhibitor-based therapies and to monitor the development of liver cirrhosis and hepatocellular carcinoma (Hasegawa et al., 2015).